Short Bowel Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Short Bowel Syndrome Pipeline Drugs Market Report Overview

Short bowel syndrome is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Symptoms include bloating, cramping, fatigue, heartburn, vomiting, weakness, and diarrhea. Complications of short bowel syndrome include malnutrition, peptic ulcers, kidney stones, and small intestinal bacterial overgrowth. Treatment includes vitamin and mineral supplements, antibiotics, proton pump inhibitors, and bile-salt binders

The Short Bowel Syndrome pipeline drugs market research report provides comprehensive information on the therapeutics under development for Short Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Short Bowel Syndrome and features dormant and discontinued projects.

Short Bowel Syndrome Pipeline Drugs Market Segmentation by Targets

Some of the targets of the Short Bowel Syndrome pipeline drugs market are Glucagon Like Peptide 2 Receptor, Glucagon Like Peptide 1 Receptor, and Cystic Fibrosis Transmembrane Conductance Regulator. Glucagon Like Peptide 2 Receptor leads this segment of the Short Bowel Syndrome pipeline drugs market.

Short Bowel Syndrome Pipeline Drugs Market Analysis, by Targets

For more Short Bowel Syndrome pipeline drugs market target insights, download a free report sample

Short Bowel Syndrome Pipeline Drugs Market Segmentation by Mechanisms of Action

Some of the key mechanisms of action of the Short Bowel Syndrome pipeline drugs market are Glucagon Like Peptide 2 Receptor Agonist, Glucagon Like Peptide 1 Receptor Agonist, and Cystic Fibrosis Transmembrane Conductance Regulator Blocker. Glucagon Like Peptide 2 Receptor Agonist leads the Short Bowel Syndrome pipeline drugs market in terms of MoA.

Short Bowel Syndrome Pipeline Drugs Market Analysis, by Mechanisms of Action

For more mechanisms of action insights into the Short Bowel Syndrome pipeline drugs market, download a free report sample

Short Bowel Syndrome Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Short Bowel Syndrome pipeline drugs market are subcutaneous, oral, intravenous, and parenteral. Subcutaneous leads the Short Bowel Syndrome pipeline drugs market in terms of RoA.

Short Bowel Syndrome Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the Short Bowel Syndrome pipeline drugs market, download a free report sample

Short Bowel Syndrome Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the Short Bowel Syndrome pipeline drugs market are recombinant peptide, fusion protein, peptide, small molecule, and recombinant protein among others. Recombinant Peptide leads the Short Bowel Syndrome pipeline drugs market in terms of molecule types.

Short Bowel Syndrome Pipeline Drugs Market Analysis, by Molecule Types

For more molecule-type insights into the Short Bowel Syndrome pipeline drugs market, download a free report sample

Short Bowel Syndrome Pipeline Drugs Market - Competitive Landscape

Some key companies in the Short Bowel Syndrome pipeline drugs market are 9 Meters Biopharma Inc, Hanmi Pharmaceuticals Co Ltd, Amogen Pharma Pvt Ltd, and Applied Molecular Transport Inc, among others. 9 Meters Biopharma Inc has the highest number of products under development.

Short Bowel Syndrome Pipeline Drugs Market Analysis, by Companies

To know more about the Short Bowel Syndrome pipeline drugs market companies, download a free report sample

Short Bowel Syndrome Pipeline Drugs Market Report Overview

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Short Bowel Syndrome.
• The pipeline guide reviews pipeline therapeutics for Short Bowel Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Short Bowel Syndrome therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Short Bowel Syndrome therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for Short Bowel Syndrome

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Short Bowel Syndrome.
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding the Short Bowel Syndrome pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.